Skip to main content


Archived News

By News

Press Releases


June 2015 Media article “Chinese Herbal Medicine May Have Delayed Benefit in Stroke”

A press article detailing the exciting new clinical results of CHIMES-E study showing the persisting benefits of NeuroAiD in post-stroke recovery was published online on

June 2015 Press Release “NeuroAiD™ has shown persistent long-term benefits after an initial 3-month treatment following stroke onset”

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients recovery after an ischemic stroke. The CHIMES-E study results were first announced by Prof. Christopher Chen (CHIMES-E co-principal investigator) during the European Stroke Organization Conference (ESOC 2015) in Glasgow, April 1719, as part of the Scientific Program during the Clinical Trial session.



August 2014 Presentation 27th August 2014 – Moleac’s CEO, David Picard, presented on “E-Commerce: Going beyond the traditional visibility of Pharma Products” at the Pharmaceutical Congress Asia that was held from 26th to 29th August 2014 at the Park Royal Hotel in Singapore. His presentation included an introduction to NeuroAiD™ as well as Moleac’s Corporate Social Responsibility (CSR) activities and commitment to patient care via the Stroke Recovery Coach. EN
July 2014 Press Article “TCM trial for stroke survivors – Professor Christopher Chen is interviewed about the NeuroAiD™II in Vascular Cognitive Impairment Study (NEURITES) in The Straits Times.” EN      
July 2014 Press Article “NUS studies the efficacy of traditional Chinese Medicine in treating stroke’s after-effects – featured in Lian He Zao Pao” CH      
April 2014 Press Release Moleac is happy to announce the appointment of Elmar Schnee as non-executive Chairman of the company EN      
Jan – Feb 2014 Press Article “Demonstrated efficiency of NeuroAiD™”

A press article detailing the exciting latest clinical data on vascular events reduction after a stroke has been published in the magazine “Actifs”

EN / FR      


Oct 2013 Press Release NeuroAiD™, a treatment for post-stroke recovery, reduced early cardiovascular events and deaths by half after stroke

Singapore, 21st October 2013 – Early vascular events are an important cause of morbidity and mortality in the first three months after a stroke. The CHIMES Study is a placebo-controlled trial of NeuroAiD™, having included 1099 patients with ischemic stroke and receiving appropriate secondary prevention treatments. The frequency of early cardiovascular events and deaths during the 3-month follow-up was significantly halved in the NeuroAiD™, group (p=0.025) without an increase in bleeding rate and non-vascular deaths.

Jul 2013 Radio Interview Presenter of ‘Body & Soul’ program on 938LIVE Daniel Martin interviews Prof Christopher Chen on Stroke in Singapore and the CHIMES Study.

938LIVE is a poplar news-focused radio station. ‘Body & Soul’, since it first aired in 2007, has been Singapore’s only dedicated daily health radio talk-show.

Jun 2013 Press Release Stroke Treatment based on Traditional Chinese Medicine increases chances of recovery

  • CHIMES Society, a unique international partnership of experts in strokes undertakes first large-scale endeavour to investigate the use of a treatment derived from natural substances in stroke management.
  • Rigorous study shows ischemic stroke patients of intermediate severity who take NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence and being able to perform daily activities at the end of three months.
  • Effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
Mar 2013 Press Release NeuroAiD™, a stroke treatment based on traditional Chinese medicine, more than doubles the chances of achieving independence after stroke

Singapore, March 19 2013: Authors of a medical paper published in this month’s Cerebrovascular Diseases journal found that NeuroAiD™ significantly improves patients’ independence after suffering a stroke compared to other control groups. During the studies stroke patients taking NeuroAiD™ were twice as likely able to take care of themselves and speak freely. The study also showed that NeuroAiD™ improved patients’ chances of performing daily activities after stroke.

Jan 2013 Media Coverage NurAiD™II is featured on France 24 with an interview with neurologist and prescriber Dr Charles Siow, CEO David Picard and lead investigator of the CHIMES trial Prof Christopher Chen about bringing Chinese medicine into the Western standards to fill the gap of improving recovery after stroke. EN      


Jul 2011 Press Release Moleac Announces the Beneficial Effect of NeuroAiD (TM) (MLC 901) in Protecting the Brain Against Global Ischemia

“Neuropharmacology” published a paper establishing NeuroAiD’s reparativeeffects on global cerebral ischemia.

Feb 2011 Press Release Prof. Michel Lazdunski receives Gold Medal from the Jung Foundation for his work on ion channels.

We are happy to announce that Prof. Michel Lazdunski, vice president research of Moleac, has been awarded one of the most prestigious international awards – the 2011 Gold Medal of the Jung Foundation for Science and Research, for his work on ion channels.



Mar 2010 Press Release Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award

Moleac Pte Ltd has been granted the Emerging Company of the Year 2010 Award, by Biospectrum, the leading integrated media platform for the Life Science Industry in Asia Pacific.

Feb 2010 Press Release Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD

The January issue of “Neuropharmacology”, publishes the article entitled “Neuroprotective and Neuroproliferative Activities of NeuroAiD”, reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.



Sep 2009 The Business Times Faster, cheaper way to developing drugs (next paragraph) Moleac’s hybrid approach has been used to successfully develop and market its stroke recovery drug in 3 years, for less than US$10m EN      
Apr 2009 Press Release Moleac named Singapore Entrepreneurial Company of the year at the Frost & Sullivan Excellence in Healthcare Award

An important confirmation of Moleacs outstanding performance in 2008.

Apr 2009 The Business Time Moleac is rewarded for its stroke treatment drug NeuroAiD EN      
Apr 2009 Medical Tribune TCM agent shows promise in post-stroke recovery, says study
An article on clinical trials performed in China shows promising results and paves the first steps towards making NeuroAiD an evidence-based medicine.
Feb 2009 Press Release Moleac Prof. Michel Lazdunski appointed as Vice-President Research of Moleac Pte. Ltd.

A world-renown scientific leader is now in charge of the study on NeuroAiD mechanism of action.

Feb 2009 Medical Tribune Evidence-based TCM makes headway
NeuroAiD™ is one of the first TCM medications to be put under the microscope of rigidly-controlled clinical trials CHIMES continues to make noises in Singapore and giving hope to stroke patients.


Dec 2008 BioSpectrum Ancient medicines, source of Pharma innovation – Moleac aims to bring the science behind traditional medicines to the next level and establishes their quality and safety through accepted modern evaluation practices. EN      
Oct 2008 Le Quotidien du Medecin (original in French) Un composé issu de la médecine chinoise au banc d’essai. L’un des magazines les plus renommés parmi les médecins français a accordé une attention particulière à NeuroAiD™.

A mixture derived from Chinese medicine on trial. One of the most prestigious magazine for doctors in France has paid special attention to NeuroAid&trade.

May 2008 The Edge Bridging the gap between East and West – Moleac unique business model differs itself from other biotech companies in valuations or the way in which the investors consider. EN      
Apr 2008 The Business
Times Weekend News
China Stroke Drug Holds Promise. EN      
Apr 2008 The Business
Times Weekend News
Three-Minute Digest: US$3.5M
more for Moleac for stroke drug


Sep 2007 The Business
Times Weekend
Largest TCM trial outside China. EN      
Sep 2007 Singapore Straits Times TCM drug for stroke to undergo clinical trials. EN      
Sep 2007 Channel News Asia Channel News Asia 880 stroke patients in Singapore to undergo TCM clinical trial. EN wmv
Sep 2007 The Business Times The Business Times Moleac plans to test traditional Chinese stroke drug. EN      
Sep 2007 Moleac announces CHIMES Largest ever clinical trial on stroke recovery medication to be initiated in Singapore and Philippines. EN      
Sep 2007 Reuters Singapore firm tests traditional Chinese stroke drug. EN      
May 2007 Medical News Today Going West with Eastern Medicine. EN      
Apr 2007 AsiaOne Chinese medicine to help stroke victims EN      
Apr 2007 Straits Times Rise of Traditional Chinese Medicine EN      


Dec 2006 Reuters Moleac Turns TCM into Stroke Treatment EN      
Dec 2006 Focus Autumn Moleac: Therapeutics from East to West. EN      
Dec 2006 Today’s Manager Uncovering New Drugs from Traditional Cures. EN      
Oct 2006 The Business Times New TCM drug offers hope for stroke patients. EN      
Sep 2006 Press release Moleac and China healthcare tie up to offer a more comprehensive rehabilitation treatment for stroke patients. EN      
Aug 2006 The Edge Traditional Therapy EN      
Aug 2006 Talking Science (children magazine) East meets West EN      
Aug 2006 EZHealth NeuroAiD for stroke patients EN      
Jun 2006 Press release NeuroAiD offers new hope to patients EN      
Apr 2006 Singapore Business Visitor The Next Wave EN      
Jan 2006 Asia Pacific Biotech Journal Moleac: Flowing Therapeutics from the East to the West and Expertise from the West to the East. EN      

Chinese Herbal Medicine May Have Delayed Benefit in Stroke

By News

VIENNA, Austria — Long-term follow-up of a trial investigating a Chinese herbal supplement in patients with stroke suggests there may be some benefit after 6 to 18 months.

The Chinese Medicine NeuroAiD Efficacy on Stroke Recovery (CHIMES) study was an international randomized double-blind placebocontrolled trial of 3 months of treatment with the herbal supplement NeuroAiD (Moleac) started within 72 hours of symptom onset in 1100 patients with ischemic stroke.

The primary results, which were reported in 2013, showed a trend toward better functional outcomes in the treated group at 3 months, but this did not reach statistical significance.

Longer-term follow-up in the CHIMES-E (Extension) study, which reported outcomes up to 2 years in 880 patients, was reported by Narayanaswamy Venketasubramanian, MD, from the Raffles Neuroscience Centre, Singapore, here at the 24th European Stroke Conference (ESC).

“While the benefits of a 3-month treatment with NeuroAiD did not reach statistical significance for the primary endpoint at 2 years, the odds of functional independence defined as [modified Rankin Scale score] ≤ 1 was significantly increased at 6 months and persisted up to 18 months after a stroke,” he concluded.

The results were also published online April 22 in Cerebrovascular Diseases.

The CHIMES-E study population had an overall mean age of 61.8 years, with 318 (36%) women, and a mean baseline National Institutes of Health Stroke Scale score of 8.6. The treatment and placebo groups were balanced in baseline characteristics at the time of inclusion in CHIMES, and they were similar in terms of subsequent rehabilitation and intake of any Chinese herbal medicines during the study, the researchers state.

The primary endpoint of the extended follow-up study was the shift analysis on the modified Rankin Scale at 2 years. This was not significant but showed a trend toward benefit with NeuroAiD (odds ratio, 1.08; 95% confidence interval, 0.85 – 1.37; P = .543).

However, when analyzed according to patients showing a good functional outcome (modified Rankin Scale, 0 – 1), treatment was associated with significant benefit at the 6-, 12-, and 18-month points.


Dr Venketasubramanian noted that the Barthel index showed similar trends toward improvements in the treated group in the longterm follow-up. “So our results are consistent on more than one score.”

“It appears that a 3-month course of treatment may not show benefits immediately,” he commented to Medscape Medical News. “Our results suggest that we may have to wait a while to see the effects, and maybe treatment should be maintained longer term, to maximize effects.”

He added: “When the brain is injured it takes time to calm down, so differences in healing may take time to show up. The herbal extracts have shown neuroprotection and neuro-restoration properties in animal models. As the results appear to be delayed, this may suggest more restoration is taking place.”

The researchers are now in discussions about conducting a second trial with a longer period of therapy and a longer follow-up.

NeuroAiD is a combination of nine Chinese herbal extracts and nine animal components. A new formulation has recently been developed without the animal components, Dr Venketasubramanian said.

“We are hoping that the new formulation, which is manufactured in accordance with good clinical practice, will mean fewer tablets and a less expensive production process. It will also have the advantage of not needing the regulation necessary for animal products.”

Marketing information produced by Moleac claims that the herbal extracts contained in NeuroAiD have been shown to “stimulate brain self repair processes for stroke recovery.” This includes “increasing the number of mature neuronal cells” in mice models and “increasing neurite outgrowth and synaptogenesis” in neuronal cell cultures. It adds that the product reduced infarct volume in a rodent stroke model, increased cell survival, and “activates ATP-dependent K+ channels contributing to neuroprotection and ischemic preconditioning.”

The product is sold as an herbal supplement and is not regulated as a medicine at present.

The CHIMES-E study was supported by the CHIMES Society, a nonprofit organization, and grants were received by CLHC from the National Medical Research Council of Singapore. The authors received funding for the trial and accommodation and transportation support for meetings from the CHIMES Society. Moleac (Singapore) provided grants to the CHIMES Society, of which the society had sole discretion on use. One coauthor has minor shares in E*Chimes, the Philippine distributor of NeuroAiD. Other than CHIMES funding for the trial, the other authors and investigators have disclosed no relevant financial relationships.

Cerebrovasc Dis. 2015;39:309-318. Full text

24th European Stroke Conference (ESC). Presented May 14, 2015.